Pathophysiological Role and Clinical Significance of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Bound to LDL and HDL

Author(s): Constantinos C. Tellis, Alexandros D. Tselepis

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 40 , 2014

Become EABM
Become Reviewer
Call for Editor


Lipoprotein-associated phospholipase A2 (Lp-PLA2), also named as platelet-activating factor (PAF)-acetylhydrolase, exhibits a Ca2+-independent phospholipase A2 activity and catalyzes the hydrolysis of the ester bond at the sn-2 position of PAF and oxidized phospholipids (oxPL). These phospholipids are formed under oxidative and inflammatory conditions, and may play important roles in atherogenesis. The vast majority of plasma Lp-PLA2 mass binds to low-density lipoprotein (LDL) while a smaller amount is associated with high-density lipoprotein (HDL). Lp-PLA2 is also bound to lipoprotein (a) [Lp(a)], very low-density lipoprotein (VLDL) and remnant lipoproteins. Several lines of evidence suggest that the role of plasma Lp-PLA2 in atherosclerosis may depend on the type of lipoprotein particle with which this enzyme is associated. Data from large Caucasian population studies have supported plasma Lp-PLA2 (primarily LDL-associated Lp-PLA2) as a cardiovascular risk marker independent of, and additive to, traditional risk factors. On the contrary, the HDL-associated Lp-PLA2 may express antiatherogenic activities and is also independently associated with lower risk for cardiac death. The present review presents data on the biochemical and enzymatic properties of Lp-PLA2 as well as its structural characteristics that determine the association with LDL and HDL. We also critically discuss the possible pathophysiological and clinical significance of the Lp- PLA2 distribution between LDL and HDL in human plasma, in view of the results of prospective epidemiologic studies on the association of Lp-PLA2 with future cardiovascular events as well the recent studies that evaluate the possible effectiveness of specific Lp-PLA2 inhibitors in reducing residual cardiovascular risk.

Keywords: Atherosclerosis, Cardiovascular disease, Darapladib, Lipoproteins, LDL, HDL, Lp-PLA2.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [6256 - 6269]
Pages: 14
DOI: 10.2174/1381612820666140622200916
Price: $65

Article Metrics

PDF: 75